Randomized phase III trial of paclitaxel plus topotecan versus topotecan plus cisplatin in recurrent or persistent cervical cancer stage IVb

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN77165120

Enrollment

326

Registered

2006-05-15

Start date

2006-02-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced carcinoma of the cervix uteri Cancer Cervical cancer

Interventions

Patients are randomised to receive one of the following: 1. Paclitaxel and topotecan 2. Topotecan and cisplatin

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients with progressive histologically confirmed carcinoma of the cervic uteri and measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST]) without treatment alternatives to chemotherapy

Exclusion criteria

Exclusion criteria: Bilateral hydronephrosis, central nervous system (CNS)-metastases or reduced general condition

Design outcomes

Primary

Measure	Time frame
Overall-survival	—

Secondary

Measure	Time frame
1. Time to progression 2. Efficacy 3. Therapy tolerance 4. Quality of life	—

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026